NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis $11.59 +0.24 (+2.11%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$11.36 -0.23 (-2.03%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Absci Stock (NASDAQ:ABSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Absci alerts:Sign Up Key Stats Today's Range$10.99▼$11.7850-Day Range$3.68▼$11.5952-Week Range$2.24▼$12.06Volume5.81 million shsAverage Volume7.85 million shsMarket Capitalization$1.81 billionP/E RatioN/ADividend YieldN/APrice Target$12.57Consensus RatingModerate Buy Company Overview Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications. The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework. By integrating AI-driven protein design with advanced screening processes, the company seeks to rapidly advance promising biologic candidates from concept through lead optimization. Absci’s platform supports research in areas such as oncology, immunology and metabolic disease, providing partners with drug-like protein candidates and data insights that can de-risk preclinical development. Founded in 2018 and headquartered in Seattle, Washington, Absci maintains collaborative relationships with multiple global pharmaceutical organizations and operates additional research facilities in the United States. The company’s leadership team brings together experts in protein engineering, data science and drug development, aiming to transform biologics discovery through technological innovation. As Absci continues to expand its pipeline partnerships and platform capabilities, it remains focused on delivering scalable solutions for the next generation of protein therapeutics.AI Generated. May Contain Errors. Read More Absci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreABSI MarketRank™: Absci scored higher than 38% of companies evaluated by MarketBeat, and ranked 654th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingAbsci has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Absci is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbsci has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Absci's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.71) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -13.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -13.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 9.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Absci's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.90% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 6.67.Change versus previous monthShort interest in Absci has recently increased by 3.97%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.55 News SentimentAbsci has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Absci this week, compared to 5 articles on an average week.Search InterestOnly 22 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows11 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Absci insiders have not sold or bought any company stock.Percentage Held by Insiders10.49% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABSI Stock News HeadlinesAbsci (NASDAQ:ABSI) Upgraded at Wall Street ZenJune 27, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX)June 26, 2026 | theglobeandmail.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?June 26, 2026 | finance.yahoo.comAbsci Corporation (NASDAQ:ABSI) Given Consensus Rating of "Moderate Buy" by AnalystsJune 26, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD) and AbSci (ABSI)June 25, 2026 | theglobeandmail.comAbsci (NASDAQ:ABSI) Reaches New 52-Week High - What's Next?June 25, 2026 | americanbankingnews.comBest Artificial Intelligence Stocks To Add to Your Watchlist - June 24thJune 25, 2026 | americanbankingnews.comSee More Headlines ABSI Stock Analysis - Frequently Asked Questions How have ABSI shares performed this year? Absci's stock was trading at $3.49 at the beginning of the year. Since then, ABSI stock has increased by 232.1% and is now trading at $11.59. How were Absci's earnings last quarter? Absci Corporation (NASDAQ:ABSI) issued its earnings results on Thursday, May, 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The company earned $0.22 million during the quarter, compared to analyst estimates of $1.39 million. Absci had a negative trailing twelve-month return on equity of 66.32% and a negative net margin of 6,450.76%. Read the conference call transcript. When did Absci IPO? Absci (ABSI) raised $200 million in an initial public offering on Thursday, July 22nd 2021. The company issued 12,500,000 shares at $15.00-$17.00 per share. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Absci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Absci investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2026Today6/30/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ABSI's financial health is in the Green zone, according to TradeSmith. ABSI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolNASDAQ:ABSI CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees210Year Founded2011Price Target and Rating Average Price Target for Absci$12.57 High Price Target$16.00 Low Price Target$10.00 Potential Upside/Downside+8.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$115.18 million Net Margins-6,450.76% Pretax Margin-6,445.81% Return on Equity-66.32% Return on Assets-57.01% Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual Sales$2.80 million Price / Sales645.31 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / Book9.20Miscellaneous Outstanding Shares155,900,000Free Float139,551,000Market Cap$1.81 billion OptionableOptionable Beta2.44 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ABSI) was last updated on 7/1/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Absci With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
